Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux

Alterations in the autophagic pathway are associated with the onset and progression of various diseases. However, despite the therapeutic potential for pharmacological modulators of autophagic flux, few such compounds have been characterised. Here we show that clomipramine, an FDA-approved drug long used for the treatment of psychiatric disorders, and its active metabolite desmethylclomipramine (DCMI) interfere with autophagic flux. Treating cells with DCMI caused a significant and specific increase in autophagosomal markers and a concomitant blockage of the degradation of autophagic cargo. This observation might be relevant in therapy in which malignant cells exploit autophagy to survive stress conditions, rendering them more susceptible to the action of cytotoxic agents. In accordance, DCMI-mediated obstruction of autophagic flux increased the cytotoxic effect of chemotherapeutic agents. Collectively, our studies describe a new function of DCMI that can be exploited for the treatment of pathological conditions in which manipulation of autophagic flux is thought to be beneficial.

[1]  G. de Murcia,et al.  PARP-1 is involved in autophagy induced by DNA damage , 2009, Autophagy.

[2]  David P. Davis,et al.  Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents , 2008, The Journal of cell biology.

[3]  G. Mills,et al.  Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. , 2008, Cancer research.

[4]  A. Calcabrini,et al.  The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells , 2008, Autophagy.

[5]  B. Levine,et al.  Eating the enemy within: autophagy in infectious diseases , 2008, Cell Death and Differentiation.

[6]  T. Mizushima,et al.  Structural Basis for Sorting Mechanism of p62 in Selective Autophagy* , 2008, Journal of Biological Chemistry.

[7]  G. Pilkington,et al.  Approaches to mitochondrially mediated cancer therapy. , 2008, Seminars in cancer biology.

[8]  Daniel J. Klionsky,et al.  Autophagy fights disease through cellular self-digestion , 2008, Nature.

[9]  M. Czaja,et al.  Loss of Macroautophagy Promotes or Prevents Fibroblast Apoptosis Depending on the Death Stimulus*♦ , 2008, Journal of Biological Chemistry.

[10]  John L Cleveland,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes , 2008, Autophagy.

[11]  C. Thompson,et al.  Autophagy: basic principles and relevance to disease. , 2008, Annual review of pathology.

[12]  Guido Kroemer,et al.  Autophagy in the Pathogenesis of Disease , 2008, Cell.

[13]  John L Cleveland,et al.  Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. , 2008, The Journal of clinical investigation.

[14]  C. Dang.  Antimalarial therapy prevents Myc-induced lymphoma. , 2008, The Journal of clinical investigation.

[15]  Masaaki Komatsu,et al.  Homeostatic Levels of p62 Control Cytoplasmic Inclusion Body Formation in Autophagy-Deficient Mice , 2007, Cell.

[16]  Robin Mathew,et al.  Role of autophagy in cancer , 2007, Nature Reviews Cancer.

[17]  Wenqing Cai,et al.  Small molecule regulators of autophagy identified by an image-based high-throughput screen , 2007, Proceedings of the National Academy of Sciences.

[18]  I. Ciechomska,et al.  Non-Autophagic GFP-LC3 Puncta Induced by Saponin and Other Detergents , 2007, Autophagy.

[19]  D. Klionsky,et al.  Protein turnover via autophagy: implications for metabolism. , 2007, Annual review of nutrition.

[20]  P. Gillman.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated , 2007, British journal of pharmacology.

[21]  J. Cleveland,et al.  Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. , 2007, Blood.

[22]  S. Schreiber,et al.  Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. , 2007, Nature chemical biology.

[23]  K. Tanaka,et al.  Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons , 2007, Cell Death and Differentiation.

[24]  B. Levine,et al.  Cell biology: Autophagy and cancer , 2007, Nature.

[25]  D. Rubinsztein,et al.  Potential therapeutic applications of autophagy , 2007, Nature Reviews Drug Discovery.

[26]  G. Evan,et al.  Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.

[27]  Per O. Seglen,et al.  Methods for Monitoring Autophagy from Yeast to Human , 2007, Autophagy.

[28]  P. Kujala,et al.  Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent‐resistant membrane compartments , 2006, Journal of neurochemistry.

[29]  Veronica Canadien,et al.  ALIS are Stress-Induced Protein Storage Compartments for Substrates of the Proteasome and Autophagy , 2006, Autophagy.

[30]  S. Tooze,et al.  Microtubules Facilitate Autophagosome Formation and Fusion of Autophagosomes with Endosomes , 2006, Traffic.

[31]  Bryan L. Roth,et al.  Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery , 2005, Nature Reviews Drug Discovery.

[32]  M. Colombo.  Pathogens and autophagy: subverting to survive , 2005, Cell Death and Differentiation.

[33]  Raymond Sawaya,et al.  The role of autophagy in cancer development and response to therapy , 2005, Nature Reviews Cancer.

[34]  A. Tolkovsky,et al.  The Dynamics of Autophagy Visualised in Live Cells: from Autophagosome Formation to Fusion with Endo/lysosomes , 2005, Autophagy.

[35]  D. Kendall,et al.  Chlorimipramine: a novel anticancer agent with a mitochondrial target. , 2005, Biochemical and biophysical research communications.

[36]  N. Mizushima.  Methods for monitoring autophagy. , 2004, The international journal of biochemistry & cell biology.

[37]  P. Glynn,et al.  Neuropathy Target Esterase and Its Yeast Homologue Degrade Phosphatidylcholine to Glycerophosphocholine in Living Cells* , 2004, Journal of Biological Chemistry.

[38]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[39]  E. Camouzis,et al.  On the Dynamics of , 2003 .

[40]  P. Glynn,et al.  Neuropathy target esterase. , 1999, The Biochemical journal.

[41]  C. Faravelli,et al.  Clinical Response and Tricyclic Plasma Levels During Treatment with Clomipramine , 1979, British Journal of Psychiatry.

[42]  J. Lünemann,et al.  Autophagy in CD4+ T-cell immunity and tolerance , 2009, Cell Death and Differentiation.

[43]  E. Morselli,et al.  Control of autophagy by oncogenes and tumor suppressor genes , 2009, Cell Death and Differentiation.

[44]  P. Codogno,et al.  Does autophagy have a license to kill mammalian cells? , 2009, Cell Death and Differentiation.

[45]  K. Brøsen,et al.  Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism , 2005, European Journal of Clinical Pharmacology.

[46]  S. Pattingre,et al.  Analyses of Galpha-interacting protein and activator of G-protein-signaling-3 functions in macroautophagy. , 2004, Methods in enzymology.

[47]  S. Vandel,et al.  Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response , 2004, European Journal of Clinical Pharmacology.

[48]  D. Klionsky,et al.  Autophagy, cytoplasm-to-vacuole targeting pathway, and pexophagy in yeast and mammalian cells. , 2000, Annual review of biochemistry.

[49]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.